Actinium Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATNM 2830 www.actiniumpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 - Dec 12th, 2025 6:45 am
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? - Dec 5th, 2025 7:40 am
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium - Dec 1st, 2025 6:45 am
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year? - Nov 19th, 2025 7:41 am
Actinium: Q3 Earnings Snapshot - Nov 14th, 2025 3:01 pm
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications - Nov 4th, 2025 5:30 am
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference - Nov 3rd, 2025 6:30 am
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 27th, 2025 5:00 am
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - Oct 24th, 2025 6:30 am
Sector Update: Health Care Stocks Advance Monday Afternoon - Oct 13th, 2025 11:42 am
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 13th, 2025 10:10 am
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - Oct 13th, 2025 6:30 am
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? - Sep 18th, 2025 7:40 am
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? - Sep 2nd, 2025 7:40 am
Actinium: Q2 Earnings Snapshot - Aug 8th, 2025 3:15 pm
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit - Jul 31st, 2025 6:30 am
Actinium Highlights ATNM 400 Progress at SNMMI Conference - Jul 2nd, 2025 8:05 pm
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting - Jun 23rd, 2025 9:30 am
Life Sciences Investor Forum: Now Available for Online Viewing - Jun 13th, 2025 6:35 am
Life Sciences Investor Forum Agenda Announced for June 11th-12th - Jun 10th, 2025 12:38 pm